NVAX

#1737
Novavax, Inc. - Common Stock
10.9 7 USD
+6.30%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
10.97
10.97
Rango anual
6.13
11.97
Cambio diario
+6.30%
Variación mensual
+36.95%
Variación en los últimos 6 meses
+60.15%
Cambio anual
+54.94%
Cierres anteriores
10.3 2
Open
10.9 7
Mínimo
10.9 7
High
10.9 7
Volumen
127
Ver el calendario completo Full chart

Financials

Visión general Informes Estadísticas Dividendos
Trimestre Año
  • Market Capitalization 1.8 B
  • Employee 749
  • Founded 1987
  • CEO John C. Jacobs
  • Website www.novavax.com
  • Headquarter Delaware, United States
  • FIGI BBG000NVSBL7
  • Industry Biotecnología
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
2.6
Relación precio/flujo de caja
1.04

Novavax, Inc. - Common Stock

Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria. Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine.

Noticias